Shingrix vaccine linked to lower cardiovascular disease risk

A study published in Nature Medicine suggests that the Shingrix shingles vaccine may be linked to a reduced risk of cardiovascular disease. Researchers utilized a natural experiment involving the transition in the United States from the older Zostavax vaccine to the recombinant Shingrix vaccine to minimize bias.

Analyzing health records of adults aged 60 and older over a seven-year period, the study found that those receiving the Shingrix vaccine experienced a lower risk of cardiovascular events during the first three and a half years following vaccination. Specific findings include a 12% lower risk of heart failure and a 12% lower burden of ischemic stroke among men. The vaccine was also associated with a 10% lower burden of ischemic heart disease and a 7% lower burden of atrial fibrillation.

Lead researcher Dr. Maxime Taquet of the University of Oxford noted that if these findings are confirmed through randomized clinical trials, vaccinating older adults could potentially prevent hundreds of thousands of cases of coronary heart disease, strokes, and heart failure worldwide. However, the researchers emphasized that the current observational study does not prove causation, and further trials are required to confirm a direct cardioprotective effect.